Los Angeles, CA – February 18, 2009 – Cardo Medical (OTCBB: CDOM), a company engaged in the development of orthopedic medical devices, has successfully introduced its femur-first option to surgeons using its Uni-Compartmental Knee System. Uni-compartmental knee arthroplasty procedures otherwise known as partial knee replacements, are most commonly performed using tibial-first referencing surgical techniques. However, the Cardo Medical Uni-Compartmental Knee system now also provides surgeons with an innovative intra-operative capability employing a femur-first technique.
Dr. Andrew Yun, a highly regarded orthopedic surgeon at St. John’s Hospital in Santa Monica, CA, has already performed numerous Cardo femur-first uni-compartmental procedures and commented, “I have been extremely satisfied with the ease of use and clinical outcomes from Cardo’s Femur-first system. The Cardo engineering team has been extremely responsive, matched by high quality workmanship.” In addition, Dr. Jonathan Braslow, an orthopedic surgeon and pioneer of unicompartmental knee surgery at JFK Memorial Hospital in Indio, CA, also stated, “The new Cardo Align 360 Femur first instrumentation system eliminates the guesswork for the first cut. The instruments are elegantly engineered and user friendly, creating, a reproducible outcome each time.”
The Align 360 Uni-Compartmental Knee System, Cardo Medical’s initial product release, has been used successfully orthopedic surgeons around the country since its introduction in January 2007. System enhancements for the femur-first approach include novel, unique femoral tibial alignment (“knee jack”) instruments with dedicated alignment and resection guides.
Dr. Andrew Brooks, Chairman and Chief Executive Officer of Cardo Medical stated “ As a surgeon myself, it is my belief that many patients who undergo a more traumatic total knee replacement would actually be excellent candidates for less invasive uni-compartmental knee procedures, However, many surgeons are not comfortable with the different surgical instrumentation sets utilized in uni-knee procedures. It has been one of our chief goals at Cardo Medical to reduce the intimidation factor for unicompartmental knee surgery and thus allow surgeons interested in this procedure, to perform uni-compartmental knee replacements in as easy and reproducible manner as possible. I believe, our innovations with regards to component design, instrumentation and surgical techniques through the Align 360 platform achieve this goal”
About Cardo Medical, Inc.
Cardo Medical (OTCBB: CDOM) develops reconstructive orthopedic and spinal surgery products through advanced engineering and focuses on product development, marketing and distribution within the US market. Cardo Medical’s superior engineering talent closely collaborates with leading surgeons
around the country to create products that reduce or eliminate joint pain and allow patients to achieve more active lives. The company’s cutting edge products are specifically developed with patients, surgeons and OR staff in mind and are designed to reduce operative time, enhance surgical technique, shorten hospital stays, reduce recovery time and improve outcomes. Cardo Medical’s product portfolio includes devices for knee, hip, spinal fusion and motion preservation arthroplasty and replacement, many of which have already received FDA clearance. Cardo Medical has a robust and innovative product pipeline pending both USPTO and FDA submission and clearance.
Cardo Medical works in small, focused development teams in concert with physicians to rapidly develop products from concept to launch. We are committed to exceeding the standards by which any device company is judged. Please visit our website at www.cardomedical.com for more information on the Align 360 Uni-Compartmental Knee System in addition to our portfolio of other Reconstructive and Spinal Implant systems.
This press release contains “forward-looking statements,” as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA), regarding product development efforts and other non-historical facts about expectations, beliefs or intentions regarding the business, technologies and products, financial condition, strategies or prospects. Many factors could cause actual activities or results to differ materially from the activities and results anticipated in forward-looking statements. These factors include those described in our filings with the Securities and Exchange Commission, as well as risks inherent in funding, developing and obtaining regulatory approvals of new, commercially-viable and competitive products and treatments, including the risks that any products under development may fail, may not achieve the expected results or effectiveness and may not generate data that would support the approval or marketing of products for the ailments being studied or for other ailments. In addition, forward-looking statements also may be adversely affected by general market factors, competitive product development, product availability, federal and state regulations and legislation, the regulatory process for new products and indications, manufacturing issues that may arise, patent positions and litigation, among other factors. We do not undertake any obligation to update forward-looking statements. We intend that all forward-looking statements be subject to the safe-harbor provisions of the PSLRA.
CONTACT:
Cardo Medical, Inc.
Andrew A. Brooks, M.D., CEO
(310) 274-2036